Surmodics, Inc.
9924 West 74th Street
Eden Prarie
Minnesota
55344-3523
United States
Tel: 952-829-2700
Fax: 952-829-2743
Website: http://www.surmodics.com/
Email: info@surmodics.com
338 articles about Surmodics, Inc.
-
Surmodics to Participate in Upcoming Investor Conferences in March and April
2/27/2024
Surmodics, Inc. today announced that management will participate in the following upcoming investor conferences.
-
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
2/1/2024
Surmodics, Inc. today reported financial results for its first quarter ended December 31, 2023, and updated its financial guidance for fiscal year ending September 30, 2024.
-
Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee
1/22/2024
Surmodics, Inc. today announced successful early clinical use of the company’s Pounce™ LP (Low Profile) Thrombectomy System.
-
Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1
1/16/2024
Surmodics, Inc. today announced that first quarter of fiscal year 2024 financial results will be released before the market opens on Thursday, February 1.
-
Surmodics to Host Virtual Annual Meeting of Shareholders - January 16, 2024
1/16/2024
Surmodics, Inc. will hold its Annual Meeting of Shareholders on Thursday, February 8, at 4 p.m. CT (5 p.m. ET), as a virtual meeting.
-
Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium
11/16/2023
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial was presented by Dr. Peter A. Schneider at the 50th Annual VEITH Symposium in New York, New York.
-
Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium
11/16/2023
Surmodics, Inc. announced today that 24-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon (DCB) was presented at the 50th annual VEITH Symposium in New York, New York.
-
Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28
11/14/2023
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the 35th Annual Piper Sandler Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY from November 28-30, 2023.
-
Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance
11/8/2023
Surmodics, Inc. today reported financial results for its fourth quarter and fiscal year ended September 30, 2023, and introduced its financial guidance for the fiscal year ending September 30, 2024.
-
Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium
11/7/2023
Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium.
-
Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15
11/7/2023
35-subject SWING Trial evaluates the safety, performance of Surmodics’ Sundance™ Sirolimus Drug-Coated Balloon.
-
Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications
10/31/2023
Surmodics, Inc. (NASDAQ: SRDX), the global leader in medical device coating technologies, announced the commercial launch of its most advanced hydrophilic medical device coating technology, Preside™ hydrophilic coatings.
-
Surmodics to Report Fourth Quarter and Fiscal 2023 Financial Results on November 8
10/10/2023
Surmodics, Inc. today announced that fourth quarter of fiscal year 2023 financial results will be released before the market opens on Wednesday, November 8.
-
Surmodics to Participate in Upcoming Investor Conferences in August 2023
8/9/2023
Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced that management will participate in the following upcoming investor conferences: The Needham Virtual MedTech & Diagnostics 1x1 Conference, which is being held from August 14‑15, 2023.
-
Surmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
8/2/2023
Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, reported financial results for its third quarter ended June 30, 2023, and updated its financial guidance for its fiscal year ending September 30, 2023.
-
Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon
6/20/2023
Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced the receipt of U.S. Food and Drug Administration approval for the SurVeil™ drug-coated balloon.
-
Surmodics Receives FDA 510(k) Clearance for Pounce™ LP Thrombectomy System
6/14/2023
Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies, announced it has received U.S. Food and Drug Administration 510 clearance for its Pounce™ LP Thrombectomy System.
-
Surmodics to Participate in the Jefferies Healthcare Conference on June 8
5/25/2023
Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced that management will participate in the Jefferies Healthcare Conference, which is being held in New York, NY, from June 7-9, 2023.
-
Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
4/26/2023
Surmodics, Inc. today reported financial results for its second quarter ended March 31, 2023, and updated its financial guidance for its fiscal year ending September 30, 2023.
-
Surmodics Announces First Patient Enrolled in PROWL Registry Study Using the Pounce™ Thrombectomy System
4/20/2023
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced enrollment of the first patient in PROWL, the Pounce™ Thrombectomy System Retrospective Registry.